Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Significant Growth in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 232,100 shares, an increase of 20.0% from the January 15th total of 193,400 shares. Currently, 3.0% of the company’s stock are sold short. Based on an average daily volume of 72,900 shares, the short-interest ratio is presently 3.2 days.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MRKR shares. Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th. LADENBURG THALM/SH SH boosted their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Insider Activity

In related news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 17.35% of the company’s stock.

Institutional Trading of Marker Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invst LLC acquired a new stake in Marker Therapeutics in the third quarter valued at about $56,000. Northern Trust Corp boosted its position in Marker Therapeutics by 66.9% during the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares in the last quarter. LPL Financial LLC acquired a new stake in Marker Therapeutics in the fourth quarter valued at $248,000. Aisling Capital Management LP boosted its position in shares of Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after buying an additional 11,084 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Marker Therapeutics in the 4th quarter worth approximately $1,724,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Stock Up 1.2 %

Shares of MRKR traded up $0.02 during midday trading on Monday, reaching $1.72. 61,990 shares of the stock were exchanged, compared to its average volume of 78,471. The business’s 50-day moving average price is $2.81 and its 200 day moving average price is $3.18. Marker Therapeutics has a twelve month low of $1.48 and a twelve month high of $5.99.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.